Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21246017 | 0.81 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1MAPTRAB9A | |
| SCHEMBL28991763 | 0.81 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1MAPTRAB9A | |
| SCHEMBL15881328 | 0.78 | L3MBTL1 (0.55) | KMT2AMEN1L3MBTL1MAPTRAB9A | |
| SCHEMBL9456322 | 0.78 | RAB9A (0.58) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL14298343 | 0.77 | L3MBTL1 (0.54) | KMT2AMEN1L3MBTL1MAPTRAB9A | |
| SCHEMBL8140443 | 0.77 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1MAPTRAB9A | |
| SCHEMBL963694 | 0.75 | — | — | |
| SCHEMBL360111 | 0.74 | MAPT (0.52) | KMT2AMEN1L3MBTL1MAPTRAB9A | |
| SCHEMBL29141778 | 0.74 | NPC1 (0.55) | KMT2AMEN1L3MBTL1MAPTRAB9A | |
| SCHEMBL19699460 | 0.74 | L3MBTL1 (0.51) | KMT2AMEN1L3MBTL1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913734-B2 | Substituted aminothiazoles | BARUCH S. BLUMBERG INSTITUTE | 2021-02-09 | — | — | US | disclosed |
| US-10913734-B2 | Substituted aminothiazoles | BARUCH S. BLUMBERG INSTITUTE | 2021-02-09 | — | — | US | disclosed |
| WO-2020053373-A1 | NOVEL TRF1 MODULATORS AND ANALOGUES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2020-03-19 | — | — | WO | disclosed |
| EP-3623370-A1 | NOVEL TRF1 MODULATORS AND ANALOGUES THEREOF | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2020-03-18 | — | — | EP | disclosed |
| US-20190241552-A1 | SUBSTITUTED AMINOTHIAZOLES | BARUCH S. BLUMBERG INSTITUTE | 2019-08-08 | — | — | US | disclosed |
| US-20190241552-A1 | SUBSTITUTED AMINOTHIAZOLES | BARUCH S. BLUMBERG INSTITUTE | 2019-08-08 | — | — | US | disclosed |
| EP-3481810-A1 | SUBSTITUTED AMINOTHIAZOLES | Baruch S. Blumberg Institute (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10087173-B2 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | BARUCH S. BLUMBERG INSTITUTE | 2018-10-02 | — | — | US | disclosed |
| WO-2018013508-A1 | SUBSTITUTED AMINOTHIAZOLES | BARUCH S. BLUMBERG INSTITUTE (US) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018013508-A1 | SUBSTITUTED AMINOTHIAZOLES | BARUCH S. BLUMBERG INSTITUTE (US) | 2018-01-18 | — | — | WO | disclosed |
| EP-2592932-A2 | NOVEL TETRAHYDROPYRAZOLO[3,4-B]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2593277-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012006760-A1 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009000-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009001-A2 | NOVEL TETRAHYDROPYRAZOLO[3,4-B]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009009-A2 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012008999-A2 | TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20110257179-A1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-10-20 | — | — | US | disclosed |
| EP-2376486-A1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010079239-A1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257179-A1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM2, GRM1 | KMT2A 2333/4885MEN1 3967/4885L3MBTL1 4469/4885 |
| US-10913734-B2 | Substituted aminothiazoles | ABAT, AADAT, BCAT1 | KMT2A 662/4885MEN1 2492/4885L3MBTL1 940/4885 |
| US-10087173-B2 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | HDGF, HCCS, BCAT1 | KMT2A 281/4885MEN1 2783/4885L3MBTL1 2688/4885 |
| US-20190241552-A1 | SUBSTITUTED AMINOTHIAZOLES | ABAT, AADAT, BCAT1 | KMT2A 662/4885MEN1 2492/4885L3MBTL1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.